Home › Funds › Simplify Propel Opportunities ETF
Fund family: Simplify Exchange Traded Funds · Filed by Simplify Exchange Traded Funds (CIK 1810747) · SEC series S000078061
Ticker: SURI (C000238807)
“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 231 with, 1 against, 3 abstentions (not counted as with management). Shareholder proposals: 0 FOR, 0 AGAINST, 0 abstained, by the filing’s own vote-source field.
No item-level comparison with other Simplify Exchange Traded Funds funds is possible: no ballot item of this fund was voted by at least three other funds of the family with a clear majority.
| Proposal type | Items | Against management |
|---|---|---|
| Director Elections | 110 | 0 |
| Compensation | 34 | 0 |
| Audit-related | 33 | 0 |
| Say-on-Pay | 26 | 0 |
| Capital Structure | 25 | 1 |
| Corporate Governance | 8 | 0 |
| Shareholder Rights and Defenses | 3 | 0 |
| Extraordinary Transactions | 1 | 0 |
Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.
| Company | Meeting | Est. position | Items | Against mgmt |
|---|---|---|---|---|
| PLAINS GP HOLDINGS, L.P. | May 20, 2026 | $34M | 6 | 0 |
| DELCATH SYSTEMS, INC. | May 13, 2026 | $5M | 5 | 0 |
| CORCEPT THERAPEUTICS INCORPORATED | May 21, 2026 | $3M | 11 | 0 |
| CELLDEX THERAPEUTICS, INC. | June 25, 2026 | $2M | 12 | 0 |
| VIRIDIAN THERAPEUTICS, INC. | June 2, 2026 | $2M | 5 | 0 |
| ORCHESTRA BIOMED HOLDINGS, INC. | June 23, 2026 | $2M | 7 | 0 |
| PHATHOM PHARMACEUTICALS, INC. | May 19, 2026 | $2M | 5 | 0 |
| COMPASS PATHWAYS PLC | May 27, 2026 | $1M | 10 | 0 |
| Meeting | Company | Proposal | Fund | Mgmt |
|---|---|---|---|---|
| June 30, 2026 | INVENTIVA S.A. | Delegation of authority to the Board of Directors to increase the share capital of the Company by issuance of ordinary shares or securities giving access to the share capital of the Company immediately or in the future by the company reserved for members of a company savings plan to be set up by the Company under the conditions provided for in Article L.3332-18 et seq. of the French Code du travail, without shareholders' preferential subscription rights. | Against | For |
Meetings with a proxy contest or competing nominees (1 in 2025-2026), and how the fund voted the items on its ballot.
240 ballot items at 30 meetings in 2025-2026. Download all votes (CSV)
Recent votes against management’s recommendation at large companies.
In the 2025-2026 proxy season, Simplify Propel Opportunities ETF (SURI) voted at 30 shareholder meetings of 29 companies, on 240 ballot items in all. Where management made a recommendation, the fund followed it on 98.3% of the items and voted against it 1 time. Its most frequent area of disagreement was capital structure (1 of its votes against management). 1 of its meetings was contested.
Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026. The interactive database shows the same votes company by company, with every other fund that voted.